Skip to content

Study · Non-randomized trial · n = 27 · 2024

5 results

Increased hepatic glucagon sensitivity in totally pancreatectomised patients.

Rix I, Lund AB, Garvey LF, Hansen CP, Chabanova E, Hartmann B, Holst JJ, Vilsbøll T, Van Hall G, Knop FK

European journal of endocrinology1 Jun 2024Cited by 3 (Europe PMC)

PMID38781444 (opens in a new tab)DOI10.1093/ejendo/lvae054 (opens in a new tab)PepBankPUB-38781444
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    Glucagon infusion increased plasma glucagon to similar high physiological levels in pancreatectomised patients, diabetes patients, and controls.

    In plain wordsGlucagon infusion raised blood glucagon to similar levels in all three participant groups.

    Peptide
    Glucagon
    Outcome
    IncreasePlasma glucagon
    Study

    n = 27

    Comparator
    Saline placebo
    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    4 ng/kg/min · intravenous · 150 minAs given in this study (human).

    Source sentences

    Summary
    Glucagon infusion increased plasma glucagon to similar high physiological levels in all groups.
    1 context sentence
    Summary · context
    Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting c…
  2. 02HumanNon-randomized trialMechanism

    Glucagon increased hepatic glucose production in all groups, with greater effects in totally pancreatectomised patients than the other groups.

    In plain wordsGlucagon raised liver glucose production in all groups, with larger effects after total pancreas removal.

    Peptide
    Glucagon
    Outcome
    IncreaseHepatic glucose production
    Study

    n = 27

    Comparator
    Saline placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4 ng/kg/min · intravenous · 150 minAs given in this study (human).

    Source sentences

    Summary
    The infusion increased hepatic glucose production and decreased plasma concentration of most amino acids in all groups, with more pronounced effects in the totally pancreatectomised patients compared with the other groups.
    1 context sentence
    Summary · context
    Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting c…
  3. 03HumanNon-randomized trialMechanism

    Glucagon decreased most plasma amino acids in all groups, with greater effects in totally pancreatectomised patients than the other groups.

    In plain wordsGlucagon lowered most blood amino acids in all groups, with larger effects after total pancreas removal.

    Peptide
    Glucagon
    Outcome
    DecreasePlasma amino acids
    Study

    n = 27

    Comparator
    Saline placebo
    Outcome group
    Amino Acid Metabolism · Metabolic and weight
    Studied dose
    4 ng/kg/min · intravenous · 150 minAs given in this study (human).

    Source sentences

    Summary
    The infusion increased hepatic glucose production and decreased plasma concentration of most amino acids in all groups, with more pronounced effects in the totally pancreatectomised patients compared with the other groups.
    1 context sentence
    Summary · context
    Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting c…
  4. 04HumanNon-randomized trialMechanism

    Glucagon diminished fatty acid re-esterification in totally pancreatectomised patients but not in type 1 diabetes patients.

    In plain wordsGlucagon reduced fatty acid recycling after total pancreas removal, but not in patients with type 1 diabetes.

    Peptide
    Glucagon
    Outcome
    DecreaseFatty acid re-esterification
    Study

    n: not reported in source

    Comparator
    Saline placebo; type 1 diabetes group
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    4 ng/kg/min · intravenous · 150 minAs given in this study (human).

    Source sentences

    Summary
    Glucagon infusion diminished fatty acid re-esterification and tended to decrease plasma concentrations of fatty acids in the totally pancreatectomised patients but not in the type 1 diabetes patients.
    1 context sentence
    Summary · context
    Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting c…
  5. 05HumanNon-randomized trialMechanism

    Glucagon tended to decrease plasma fatty acids in totally pancreatectomised patients but not in type 1 diabetes patients.

    In plain wordsGlucagon tended to lower blood fatty acids after total pancreas removal, but not in patients with type 1 diabetes.

    Peptide
    Glucagon
    Outcome
    DecreasePlasma fatty acids
    Study

    n: not reported in source

    Comparator
    Saline placebo; type 1 diabetes group
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    4 ng/kg/min · intravenous · 150 minAs given in this study (human).

    Source sentences

    Summary
    Glucagon infusion diminished fatty acid re-esterification and tended to decrease plasma concentrations of fatty acids in the totally pancreatectomised patients but not in the type 1 diabetes patients.
    1 context sentence
    Summary · context
    Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting c…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.